Technical CommentsCancer

Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

See allHide authors and affiliations

Science Translational Medicine  24 May 2017:
Vol. 9, Issue 391, eaam6298
DOI: 10.1126/scitranslmed.aam6298

Article Information

vol. 9 no. 391

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication December 19, 2016
  • Accepted for publication April 21, 2017

Author Information

  1. Xiaoli Zheng1,*,
  2. Yanqing Liu1,*,
  3. Qinqin Yu1,
  4. Hua Wang2,
  5. Fuqing Tan3,
  6. Qianying Zhu1,
  7. Lingmin Yuan1,
  8. Huidi Jiang1,
  9. Su Zeng1,, and
  10. Lushan Yu1,,
  1. 1Institute of Drug and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  2. 2Department of Urology, Cancer Hospital of Zhejiang Province, Hangzhou 310022, China.
  3. 3Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
  1. Corresponding author. Email: zengsu{at}zju.edu.cn (S.Z.); yuls{at}zju.edu.cn (L.Y.)
    • * These authors contributed equally to this work.

    • Present address: College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China.

    Altmetric

    Article usage

    Article usage: May 2017 to July 2019

    AbstractFullPdf
    May 20172259228142
    Jun 201717148111
    Jul 2017994450
    Aug 2017894035
    Sep 2017993522
    Oct 2017872115
    Nov 2017853024
    Dec 2017781921
    Jan 201851158
    Feb 2018341323
    Mar 201833128
    Apr 201831164
    May 2018652428
    Jun 2018392620
    Jul 2018191625
    Aug 201853711
    Sep 201844419
    Oct 2018710824
    Nov 2018129815
    Dec 20184796
    Jan 201956312
    Feb 2019126018
    Mar 201922711
    Apr 20193188
    May 2019142925
    Jun 20197147
    Jul 2019287

    Navigate This Article